![]() |
|
|
Vol. 58, Issue 5, 1001-1010, November 2000
Drug Discovery Program, H. Lee Moffitt Cancer Center and Research
Institute, and Department of Biochemistry and Molecular Biology,
College of Medicine, University of South Florida, Tampa, Florida
Recent experiments suggest an interconnection between cell
proliferation and programmed cell death (apoptosis), although the detailed molecular mechanisms remain unclear. We have hypothesized that
expression of some apoptosis regulators is cell cycle-dependent, which
in turn influences tumor cell chemosensitivity in a cell cycle-dependent fashion. To test these hypotheses, we synchronized human leukemia Jurkat T, Neo (using aphidicolin), breast cancer MCF-7,
normal fibroblast, and simian virus 40-transformed cells (by
aphidicolin or serum starvation), and measured levels of several Bcl-2
family proteins. The highest expression of Bcl-2 protein was found in
the G1 phase of all the five cell lines tested. In contrast, levels of Bax protein remained relatively unchanged in four
of the cell lines, and levels of Bcl-XL,
Bcl-XS, and Bak proteins showed little or no cell
cycle-dependent changes in Jurkat T cells. Similar to the changes in
Bcl-2 protein levels, its mRNA expression was also G1
phase-specific, whereas the level of a Bcl-2 cleavage activity remained
constitutive. When treated with an anticancer drug (etoposide or
cisplatin) or the kinase inhibitor staurosporin, the cells containing a
high G1 population and a high Bcl-2 protein level were much
more resistant to the induced apoptosis than the cells containing a
high S phase population and a low Bcl-2 protein level. Constitutive
overexpression of Bcl-2 protein in Jurkat T cells completely blocked
the S phase-associated sensitivity to these apoptosis stimuli. The cell
cycle-dependent Bcl-2 protein expression seems to contribute to the
regulation of chemosensitivity and apoptotic commitment of human tumor cells.
This article has been cited by other articles:
![]() |
Y. Otake, S. Soundararajan, T. K. Sengupta, E. A. Kio, J. C. Smith, M. Pineda-Roman, R. K. Stuart, E. K. Spicer, and D. J. Fernandes Overexpression of nucleolin in chronic lymphocytic leukemia cells induces stabilization of bcl2 mRNA Blood, April 1, 2007; 109(7): 3069 - 3075. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. K. Sengupta, S. Bandyopadhyay, D. J. Fernandes, and E. K. Spicer Identification of Nucleolin as an AU-rich Element Binding Protein Involved in bcl-2 mRNA Stabilization J. Biol. Chem., March 19, 2004; 279(12): 10855 - 10863. [Abstract] [Full Text] [PDF] |
||||
![]() |
W.-L. Zhao, M. E. Daneshpouy, N. Mounier, J. Briere, C. Leboeuf, L.-F. Plassa, E. Turpin, J.-M. Cayuela, J.-C. Ameisen, C. Gisselbrecht, et al. Prognostic significance of bcl-xL gene expression and apoptotic cell counts in follicular lymphoma Blood, January 15, 2004; 103(2): 695 - 697. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Derenne, B. Monia, N. M. Dean, J. K. Taylor, M.-J. Rapp, J.-L. Harousseau, R. Bataille, and M. Amiot Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-xL is an essential survival protein of human myeloma cells Blood, June 17, 2002; 100(1): 194 - 199. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. W. Tolcher Novel Compounds in the Therapy of Breast Cancer: Opportunities for Integration with Docetaxel Oncologist, June 1, 2001; 6(2008): 40 - 44. [Abstract] [Full Text] [PDF] |
||||